Latest & greatest articles for rosuvastatin

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on rosuvastatin or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on rosuvastatin and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for rosuvastatin

41. Rosuvastatin in older patients with systolic heart failure. (PubMed)

Rosuvastatin in older patients with systolic heart failure. Patients with systolic heart failure have generally been excluded from statin trials. Acute coronary events are uncommon in this population, and statins have theoretical risks in these patients.A total of 5011 patients at least 60 years of age with New York Heart Association class II, III, or IV ischemic, systolic heart failure were randomly assigned to receive 10 mg of rosuvastatin or placebo per day. The primary composite outcome (...) was death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke. Secondary outcomes included death from any cause, any coronary event, death from cardiovascular causes, and the number of hospitalizations.As compared with the placebo group, patients in the rosuvastatin group had decreased levels of low-density lipoprotein cholesterol (difference between groups, 45.0%; P<0.001) and of high-sensitivity C-reactive protein (difference between groups, 37.1%; P<0.001). During a median

2007 NEJM

42. Cost-effectiveness and budget impact analysis of rosuvastatin and atorvastatin for LDL-cholesterol and cardiovascular events lowering within the SUS scenario

Cost-effectiveness and budget impact analysis of rosuvastatin and atorvastatin for LDL-cholesterol and cardiovascular events lowering within the SUS scenario Cost-effectiveness and budget impact analysis of rosuvastatin and atorvastatin for LDL-cholesterol and cardiovascular events lowering within the SUS scenario Cost-effectiveness and budget impact analysis of rosuvastatin and atorvastatin for LDL-cholesterol and cardiovascular events lowering within the SUS scenario Araujo D V, Bahia L (...) , Souza C P, Pavao A L Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study investigated the cost-effectiveness of rosuvastatin versus atorvastatin for lowering low-density lipoprotein-cholesterol and avoiding future cardiovascular

2007 NHS Economic Evaluation Database.

43. Impact of rosuvastatin use on costs and outcomes in patients at high risk for cardiovascular disease in US managed care and Medicare populations: a data analysis

Impact of rosuvastatin use on costs and outcomes in patients at high risk for cardiovascular disease in US managed care and Medicare populations: a data analysis Impact of rosuvastatin use on costs and outcomes in patients at high risk for cardiovascular disease in US managed care and Medicare populations: a data analysis Impact of rosuvastatin use on costs and outcomes in patients at high risk for cardiovascular disease in US managed care and Medicare populations: a data analysis Huse D M (...) , Song X, Ozminkowski R J, Maguire J, Williams S A, Borok G M, McDonough K Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The study examined the use of rosuvastatin in patients at high risk of cardiovascular disease. The study

2006 NHS Economic Evaluation Database.

44. Cost-effectiveness of rosuvastatin, atorvastatin, simvastatin, pravastatin and fluvastatin for the primary prevention of CHD in the UK

Cost-effectiveness of rosuvastatin, atorvastatin, simvastatin, pravastatin and fluvastatin for the primary prevention of CHD in the UK Cost-effectiveness of rosuvastatin, atorvastatin, simvastatin, pravastatin and fluvastatin for the primary prevention of CHD in the UK Cost-effectiveness of rosuvastatin, atorvastatin, simvastatin, pravastatin and fluvastatin for the primary prevention of CHD in the UK Davies A, Hutton J, O'Donnell J, Kingslake S Record Status This is a critical abstract (...) rosuvastatin (ROS), atorvastatin (ATO), simvastatin (SIM), pravastatin (PRA) and fluvastatin (FLU). Initial doses were 10 mg for ROS, ATO and SIM, 20 mg for PRA, and 40 mg for FLU. Patients who failed to reach the target cholesterol level with the initial dosage where titrated to the next highest dosage (20 and 40 mg for ROS and PRA, 20, 40 and 80 mg for ATO and SIM, and 40 and 80 mg for FLU). Type of intervention Primary prevention. Economic study type Cost-utility analysis. Study population The study

2006 NHS Economic Evaluation Database.

45. Rosuvastatin is cost-effective in treating patients to low-density lipoprotein-cholesterol goals compared with atorvastatin, pravastatin and simvastatin: analysis of the STELLAR trial

Rosuvastatin is cost-effective in treating patients to low-density lipoprotein-cholesterol goals compared with atorvastatin, pravastatin and simvastatin: analysis of the STELLAR trial Rosuvastatin is cost-effective in treating patients to low-density lipoprotein-cholesterol goals compared with atorvastatin, pravastatin and simvastatin: analysis of the STELLAR trial Rosuvastatin is cost-effective in treating patients to low-density lipoprotein-cholesterol goals compared with atorvastatin (...) , pravastatin and simvastatin: analysis of the STELLAR trial Hirsch M, O'Donnell J C, Jones P Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of rosuvastatin (10 - 40 mg/day), atorvastatin (10 - 80 mg/day), pravastatin (10 - 40 mg

2005 NHS Economic Evaluation Database.

46. Cost effectiveness of rosuvastatin in treating patients to low-density lipoprotein cholesterol goals compared with atorvastatin, pravastatin, and simvastatin (a US Analysis of the STELLAR Trial)

Cost effectiveness of rosuvastatin in treating patients to low-density lipoprotein cholesterol goals compared with atorvastatin, pravastatin, and simvastatin (a US Analysis of the STELLAR Trial) Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2005 NHS Economic Evaluation Database.

47. The cost-effectiveness of a new statin (rosuvastatin) in the UK NHS

The cost-effectiveness of a new statin (rosuvastatin) in the UK NHS The cost-effectiveness of a new statin (rosuvastatin) in the UK NHS The cost-effectiveness of a new statin (rosuvastatin) in the UK NHS Palmer S J, Brady A J, Ratcliffe A E Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment (...) on the reliability of the study and the conclusions drawn. Health technology The use of rosuvastatin, compared with other statins, for the treatment of hyperlipidaemia and the prevention of coronary heart disease (CHD). Type of intervention Primary and secondary prevention. Economic study type Cost-effectiveness analysis. Study population The target population comprised all newly diagnosed hypercholesterolaemic patients, who exceeded the UK and European target levels for TC (5 mmol/L) and LDL-C (3 mmol/L

2003 NHS Economic Evaluation Database.

48. Rosuvastatin: do we need another statin?

Rosuvastatin: do we need another statin? Rosuvastatin: do we need another statin? Rosuvastatin: do we need another statin? Ho C Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Ho C. Rosuvastatin: do we need another statin? Ottawa: Canadian Coordinating Office for Health Technology Assessment/Office Canadien de Coordination de l'Evaluation (...) des Technologies de la Sante (CCOHTA) 2001: 4 Authors' objectives To summarise the available evidence on the use of rosuvastatin for the treatment and prevention of lipid disorders. Authors' conclusions - Rosuvastatin (Crestor(TM)) is a new synthetic agent for the treatment and prevention of lipid disorders, a risk factor for coronary heart disease. - Rosuvastatin is undergoing phase III clinical trials. A New Drug Application was submitted to the U.S. Food and Drug Administration in June, 2001

2001 Health Technology Assessment (HTA) Database.